Albumedix specializes in biopharmaceutical technologies, particularly through its proprietary Veltis® platform, which utilizes engineered recombinant albumin to enhance the therapeutic performance of active pharmaceutical ingredients (APIs). This technology addresses common challenges faced by biopharmaceuticals, such as rapid inactivation and inadequate delivery to target sites, by leveraging albumin's natural properties. Veltis® allows for increased loading capacity, broad design flexibility for creating bispecific therapies, and optimized drug performance by modulating the drug's half-life. The platform's ability to target specific tissues, including inflamed areas and tumors, enhances the efficacy of treatments while potentially reducing side effects and improving patient compliance.

In addition to Veltis®, Albumedix offers a range of products and services that support biopharmaceutical development, including high-quality recombinant human albumins and customized media solutions. Their expertise spans various applications, from cell culture media to bioprocessing and quality control, ensuring that clients can effectively develop and manufacture biologics. The company emphasizes the importance of regulatory compliance and provides consulting services to help clients navigate the complexities of biopharmaceutical development, ultimately aiming to deliver effective and patient-friendly treatments to the market.

Denmark

Albumedix is an England-based biotechnology company that manufactures and markets albumins for vaccine stabilization, cell and gene therapy applications.

Albumedix

Company Details